Phosphodiesterase 4 inhibitors and inflammatory bowel disease: Emerging therapies in inflammatory bowel disease

Expert Opinion on Investigational Drugs

Volumn 16, Issue 9, 2007, Pages 1489-1506

  Keshavarzian, Ali ^a   Mutlu, Ece ^a   Guzman, Juan P ^a   Forsyth, Christopher ^a   Banan, Ali ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Crohn's disease; Phosphodiesterase; Reactive oxygen species; Tetomilast (OPC 6535); Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; COLONY STIMULATING FACTOR; CORTICOSTEROID; CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR; FERROUS SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PREDNISONE; PROTEIN KINASE C; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE; TETOMILAST; THEOPHYLLINE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; ANXIETY; ASTHMA; CATARACT; CELLULAR IMMUNITY; CHILL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COLON RESECTION; CONTINUOUS INFUSION; CROHN DISEASE; DEMYELINATION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; ENZYME ACTIVATION; ENZYME INHIBITION; FATIGUE; FECES INCONTINENCE; FEVER; FLATULENCE; FOOD; FOOD DRUG INTERACTION; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; ILEOSTOMY; ILEUM POUCH; INDIGESTION; INTESTINAL BLEEDING; LOW DRUG DOSE; LYMPHOMA; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; OXIDATIVE STRESS; PATHOGENESIS; PATIENT COMPLIANCE; PHARMACODYNAMICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; SWEATING; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VOMITING; WEAKNESS; WEIGHT GAIN; ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; HUMANS; INFLAMMATORY BOWEL DISEASES; PHOSPHODIESTERASE INHIBITORS;

EID: 34548587662     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.9.1489     Document Type: Review

References (77)

1. TRUELOVE SC: Ulcerative colitis beginning in childhood. N. Engl. J. Med. (1971) 285:50-52.
2. LANGHOLZ E, MUNKHOLM P, DAVIDSEN M, BINDER V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology (1994) 107:3-11.
3. PODOLSKY DK: Inflammatory bowel disease. N. Engl. J. Med. (2002) 347:417-429.
4. KIRSNER JB: Inflammatory bowel disease. Part II: clinical and therapeutic aspects. Dis. Mon. (1991) 37:669-746.
5. LOGAN RF: Inflammatory bowel disease incidence: up, down or unchanged? Gut (1998) 42:309-311.
6. FIOCCHI C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology (1998) 115(1):182-205.
7. MACDERMOTT RP: Alterations in the mucosal immune system in ulcerative colitis and Crohn's disease. Med. Clin. North Am. (1994) 78:1207-1231.
8. SCHREIBER S, ROSENSTIEL J, ALBRECHT M, HAMPE J, KRAWCZAK M: Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat. Rev. Genet. (2005) 6:376-388.
9. SCHRECK R, ALBERMANN K, BAEUERLE PA: NF-κB: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic. Res. Commun. (1992) 17(4):221-237.
10. WEISS SJ: Tissue destruction by neutrophils. N. Engl. J. Med. (1989) 320(6):365-376.
11. HALLIWELL B: Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet (1994) 344(8924):721-724.
12. CONNER EM, GRISHAM MB: Inflammation, free radicals, and antioxidants. Nutrition (1996) 12(4):274-277.
13. SIEBENLIST U, FRANZOSO G, BROWN K: Structure, regulation and function of NF-κB. Ann. Rev. Cell Biol. (1994) 10:405-55.
14. BLUMBERG RS, SAUBERMANN LJ, STROBER W: Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr. Opin. Immunol. (1999) 11:648-656.
15. BLUMBERG RS, STROBER W: Prospects for research in inflammatory bowel disease. JAMA (2001) 285:643-647.
16. HOLLANDER D: The intestinal permeability barrier: a hypothesis as to its regulation and involvement in Crohn's disease. Scand. J. Gastroenterol. (1992) 27:721-726.
17. ZUCKERMAN MJ, WATTS MT: Intestinal permeability to 51 Cr-EDTA in-patients with ulcerative colitis. Am. J. Gastroenterol. (1988) 88(11):1978-1979.
18. EINERHAND AW, RENES IB, MAKKINK MK, VAN DER SLUIS M, BÜLLER HA, DEKKER J: Role of mucins in inflammatory bowel disease: important lessons from experimental models. Eur. J. Gastroenterol. Hepatol. (2002) 14(7):757-765.
19. VAN DEVENTER SJ, TEN CATE JW, TYTGAT GN: Intestinal endotoxemia. Clinical significance. Gastroenterology (1988) 94:825-831.
20. HOLLANDER D: Crohn's disease - a permeability disorder of the tight junction? Gut (1988) 26:1621-1624.
21. BARNES PJ, KARIN M: NF-κB, a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. (1997) 336:1066-1071.
22. NEURATH MF, PETTERSSON S, BUSCHENEEDLE KMZ, STROBER W: Local Administration of antisense phosphorothioate oglionucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat. Med. (1999) 9(2):998-1004.
23. BANAN A, ZHANG L, FARHADI A, FIELDS JZ, KESHAVARZIAN A: Evidence that NF-κB inactivation is essential in EGF-mediated protection of the monolayer barrier function of intestinal epithelia. J. Pharmacol. Exp. Ther. (2003) 306(1):13-28.
24. BANAN A, ZRANG L, FIELDS JZ, FARHADI A, KESHAVARZIAN A: Requirement for the classical PKC isoform β1 (PKC-β1) signal in the suppression of the NF-κB/I-κBα proinflammatory patheway and in cell monolayer barrier protection by EGF under oxidative stress. Am. J. Physiol. (Cell Physiol.) (2004) 286(3):C723-C738.
25. BANAN A, ZHANG L, FIELDS JZ, FARHADI A, KESHAVARZIAN A: Role of phospholipase C-β1 isoform as the key signal in EGF-mediated suppression of both NF-κB activation and I-kBα degradation and protection of intestinal monolayers under oxidant injury. J. Pharmacol. Exp. Ther. (2004) 309(1):356-368.
26. JOBIN C, SARTOR RB: The IkB/NF-κB system: key determinant of mucosal inflammation and protection. Am. J. Physiol. (Cell) (2000) 278:C451-C462.
27. BANAN A, SHAIKH M, ZHANG L, FIELDS JZ, FARHADI A, KESHAVARZIAN A: Upregulation of NF-κB, IkBα phosphorylation (IkBα.P),iNOS, and cytoskeletal protein oxidation and dysfunction in colonic mucosa of patients with inflammatory bowel disease (IBD). Gastroenterology (2003) 124(4 Suppl. 1):S1338.
28. SCHREIBER S, NIKOLAUS S, HAMPE J: Activation of NF-κB inflammatory bowel disease. Gut (1998) 42(4):477-484.
29. BANAN A, ZHANG L, FIELDS JZ, SHAIKH M, FARHADI A, KESHAVARZIAN A. Novel effect of NF-κB activation: carbonylation and nitration injury to cytoskeleton in intestinal epithelium. Am. J. Physiol. (Cell Physiol.) (2004) 287(4):C1139-C1151.
30. BANAN A, ZHANG LJ, FARHADI A et al.: Critical role of the atypical isoform of protein kinase C (PKC-λ) in oxidant-induced disruption of the microtubule cytoskeleton and barrier function of intestinal epithelium. J. Pharmacol. Exp. Ther. (2005) 312:458-471.
31. BANAN A, FIELDS JZ, ZHANG Y, KESHAVARZIAN A: iNOS upregulation and cytoskeletal nitration explains how oxidants disrupt the cytoskeleton and increase permeability of monolayers of intestinal epithelia. Am. J. Physiol. (GI & Liver) (2001) 280:G1234-G1246.
32. DIJKSTRA G, MOSHAGE H, VAN DULLEMEN HM et al.: Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J. Pathol. (1998) 186(4):416-421.
33. KESHAVARZIAN A, BANAN A, FARHADI A et al.: Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut (2003) 52:720-728.
34. ROMANO M, POLK WH, AWAD JA et al.: Transforming growth factor α protection against drug-induced injury to the rat gastric mucosa in vivo. J. Clin. Invest. (1992) 90:2409-2421.
35. PODOLSKY DK: Peptide growth factors in the gastrointestinal tract. In: Physiology of the Gastrointestinal Tract. Johnson LR (Ed.), Vol. 1, 3rd (Edn.), Raven, New York, USA (1994):129-167.
36. BONTUREK PK, BRZOZOWSKI T, KONTUREK SJ: Role of epidermal growth factor, prostaglandin, and sulfhydryls in stress-induced gastriclesions. Gastroenterology (1990) 99:1607-1615.
37. KONTUREK SJ, BRZOZOWSKI T, BIELANSKI W. Epidermal growth factor in the gascroprotective and ulcer-healing action of sucralfate in rats. Am. J. Med. (1989) 86(Suppl. 6A):32-37.
38. BASS P, LUCK MS: Effect of epidermal growth factor on experimental colitis in the rat. J. Pharmacol. Exp. Ther. (1993) 264:984-990.
39. OLSEN PS: Role of epidermal growth factor in gastroduodenal mucosa protection. J. Clin. Gastroenterol. (1988):S146-S511.
40. OLSEN PS, POULSEN SS, KIRKEGAARD P, NEXO E: Role of submandibular saliva and epidermal growth factor in gastric cyroprotection. Gastroenterology (1984) 87:103-108.
41. GOODLAD RA, WRIGHT NA: Epidermal growth factor and transforming growth factor - actions on the gut. Eur. J. Gastroenterol. Hepatol. (1995) 7(10):928-932.
42. PLAYFORD RJ: Peptides and gastrointestinal mucosal integrity. Gut (1995) 37(5):595-597.
43. KONTUREK S, DEMBINSKI A, WARZECHA Z, BRZOZOWSKI T, GREGORY H: Role of epidermal growth factor in healing of chronic gastroduodenalulcers in rats. Gastroenterology (1988) 94:1300-1307.
44. BARNARD JA, COFFEY RJ: Increased production of transforming growth factor α following acute gastric injury. Gastroenterology (1992) 102:1467-1474.
45. BANAN A, CHOUDHARY S, ZHANG Y, KESHAVARZIAN A: Role of the microtubule cytoskeleton in protection by epidermal growth factor and transforming growth factor-α against oxidant-induced barrier disruption in a human colonic cell line. Free Radic. Bio. Med. (2000) 28(5):727-738.
46. BANAN A, CHOUDHARY S, ZHANG Y, KESHAVARZIAN A: Ethanol-induced barrier dysfunction and its prevention by growth factors in human intestinal monolayers: evidence for oxidative and cytoskeletal mechanisms. J. Pharmacol. Exp. Ther. (1999) 291(3):1075-1085.
47. BANAN A, ZHANG Y, LOSURDO J, KESHAVARZIAN A: Carbonylation and disassembly of the F-actin cytoskeleton in oxidant-induced barrier dysfunction and its prevention by epidermal growth factor and transforming growth factor-α in a human intestinal cell line. Gut (2000) 46:830-837.
48. BANAN A, FIELDS JZ, ZHANG L, KESHAVARZIAN A: PKC-Zeta (ζ) is required in EGF protection of microtubules and intestinal barrier integrity against oxidant injury. Am. J. Physiol. Gastrointest. Liver Physiol. (2002) 282(5):G794-G808.
49. BANAN A, ZHANG L, FIELDS JZ, SHAIKH M, FARHADI A, KESHAVARZIAN A: Inhibition of oxidant-induced nitration and disassembly of F-actin cytoskeleton and loss of epithelial barrier function by EGF: role of phospholipase C-γ (PLC-γ). Am. J. Physiol. (Cell Physiol.) (2003) 285(4):C977-C993.
50. BANAN A, CHOUDHARY S, ZHANG Y, KESHAVARZIAN A: Protein kinase C (PKC) is required for the protective effeccs of growth factors (GF) on microrubule cytoskeleton & intestinal epithelial barrier integrity (BI). Gastroenterology (2000) 118(4 Part 1) (Abstract).
51. BANAN A, FIELDS JZ, ZHANG L, KESHAVARZIAN A: The atypical PKC-Zera (ζ) is required for the protection of the microtubule cytoskeleton and barrier integrity of human intestinal monolayers. Am. J. Physiol. (GI & liver) (2002) 282:G794-G808.
52. BANAN A, ZHANG L, FIELDS JZ, TALMAGE DA, KESHAVARZIAN A: PKC-ζ prevents oxidant-induced iNOS upregulation and protects microtubules and intestinal barrier integrity. Am. J. Physiol. (GI & liver) (2002) 283:G909-G922.
53. BANAN A, ZHANG L, FIELDS JZ, FARHADI A, KESHAVARZIAN A: Zeta (ζ) isoform of protein kinase C prevents oxidant-induced NF-κB activation and I-kBα degradation: a fundamental mechanism for EGF protection of the microtubule cytoskeleton and intestinal barrier integrity. J. Pharmacol. Exp. Ther. (2003) 307(1):53-66.
54. NAGAMOTO H, MAEDA T, SUEYOSHI S et al.: OPC-6535 inhibits human and porcine monocyte TNF-α production in vitro and in vivo. Gastroenterology (2004) 26(4 Suppl. 2):W1090 (Abstract).
55. NAGAMOTO H, SUEYOSHI S, AOYAMA M et al.: OPC-6535, a novel thiazole compound inhibits tumor necrosis factor-α (TNF-α) production in vitro and in vivo. Am. J. Resp. Crit. Care Med. (2004) 169(7):B68 (Abstract).
56. NAGAMOTO H, MAEDA T, AOYAMA M et al.: OPC-6535, a novel thiazole compound inhibits superoxide production in leukocytes in vitro. Am. J. Resp. Crit. Care Med. (2004) 169(7):B65 (Abstract).
57. NAGAMOTO H, KAWASOME H, SUEYOSHI M et al.: OPC-6535, a novel thiazole compound, inhibits neutrophil adhesion to endothelial cells in vitro. Am. J. Resp. Crit. Care Med. (2004) 169(7):B66 (Abstract).
58. NAGAMOTO H, HARUTA J, MIYAKODA G, KIKUCHI M: The effects of OPC-6535, a novel thiazole compound, on the production of cytokines in human peripheral blood mononuclear cells in vitro. Am. J. Resp. Crit. Care Med. (2004) 169(7):B67 (Abstract).
59. HOUSLAY MD, SCHAFER P, ZHANG KY: Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov. Today (2005) 10:1503-1519.
60. KAMBAYASHI T, JACOB CO, ZHOU D, MAZUREK N, FONG M, STRASSMANN G: Cyclic nucleotide phosphodiesterase Type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. J. Immunol. (1995) 155:4909-4916.
61. NAGAMOTO H, MAEDA T, HARUTA J-P et al.: OPC-6535, a novel oral thiazole compound, suppresses colonic damage in a rat model of TNBS-induced colitis. Gastroenterology (2004) 26(4 Suppl. 2):M1044 (Abstract).
62. NAGAMOTO H, MAEDA T HARUTA J-P, MIYAKODA G, MORI T, TOMINAGA M: OPC-6535 suppresses symptoms and colonic damage in a rat model of DSS-induced chronic colitis. Gastroenterology (2004) 26(4 Suppl. 2):M1045 (Abstract).
63. MAEDA T, SUEYOSHI S, AOYAMA M et al.: Effects of intravenous or oral administration of OPC-6535 in a rat model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. Gut (1997) 4(Suppl. 3):A112 (Abstract).
64. MAEDA T, SATO N, HARUTA J et al.: Effects of OPC-6535 on a rat model of TNBS-induced colitis: its relation to produced thiobarbituric-reactive substances, IL- IΒ and TNF-α, in the colonic tissue. Ulcer Res. (2000) 27(2):198-201.
65. MIYAKADO G, MAEDA T, NAGAMOTO T, MORI M, TOMINAGA M: Effects of intravenous or oral administration of OPC-6535 in a rat model of dextran sodium sulfate (DSS)-induced colitis. Gut (1997) 41:A227.
66. BANNER KH, TREVETHICK MA: PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol. Sci. (2004) 25:430-436.
67. CHIHIRO M, NAGAMOTO H, TAKEMURA I et al.: Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: synthesis and structure-activity relationships. J. Med. Chem. (1995) 38(2):353-358.
68. MAEDA T: Effects of intravenous or oral administration of OPC-6535 in a rat model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induce colitis. Gut (1997) 41:A1112.
69. BLOOMFIELD GL, RIDINGS PC, BLOCHER CR, FISHER BJ, FOWLER AA: OPC-6535, a superoxide anion production inhibitor, attenuates acute lung injury. J. Surg. Res. (1997) 72:70-77.
70. COIMBRA R. PORCIDES RD, MELBOSTAD HI et al.: Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia. Surg. Infect. (2005) 6(1):73-85.
71. SCHREIBER S, KESHAVARZIAN A, ISSACS KL et al.: A randomized, placebo-controlled Phase II study of teromilast in active ulcerative colitis. Gastroenterology (2007) 132(1):76-86.
72. OTSUKA MARYLAND RESEARCH INSTITUTE: OPC-6535 Investigator's Brochure, Edition 9. Otsuka Report, (issued 15 December 2005).
73. International Conference on Harmonisation; Good Clinical Practice: Consolidated Guideline; Notice of Availability, 62 Federal Register (1997) 90:(9):25691-25709.
74. LANDIS RJ, HEYMAN ER, KOCH GG: Average partial association in three-way contingency tables: a review and discussion of alternative tests. Int Stat. Rev. (1978) 46:237-254.
75. KOCH G et al.: Categorical data analysis, In: Statistical Methodology in the Pharmaceutical Sciences. Berry DA (Ed.), Marcel Dekker, Inc., New York, USA (1990):414-421.
76. HOCHBERG Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika (1988) 75: 800-802.
77. SCHREIBER S, KESHAVARZIAN A, ISAACS KL: A randomized, placebo-controlled Phase II study of tetomilast in active ulcerative colitis. Gastroenterology (2007) 132(1):76-86.